美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

HORIZON KINETICS MEDICAL ETF

35.24

-0.2499-0.70%

盤後：35.250.0137+0.04%16:10 EDT

成交量：732

成交額：2.58萬

市值：1,655.92萬

市盈率：- -

高：35.25

開：35.25

低：35.24

收：35.49

52周最高：37.90

52周最低：28.87

股本：46.99萬

流通股本：46.99萬

量比：1.05

換手率：0.16%

股息：0.41

股息率：1.16%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

2026年國家醫保目錄談判收官：「三除外」落地，醫保商保雙軌並行，雙目錄如何重構創新藥支付邏輯

华夏时报网

諾華製藥(NVS.US)大股東呼籲改組董事會，以改善公司治理。此前該公司股價因連續試驗受挫於本周創下紀錄跌幅。大股東Da

Artisan Partners：在藥物試驗接連受挫後諾華應在董事會層面進行改組

信立泰重啓H股IPO，創新藥收入站上半壁江山，仍存單品依賴隱憂

ETF日報(09.10)丨臨床風險事件擾動等多因素疊加，創新藥板塊回落銀行股温和普漲

透景生命(300642.SZ)控股子公司申報醫療器械註冊獲得受理

東北證券：創新藥BD和商業化持續兑現 CXO超預期，傳統板塊築底拐點

創新藥概念股震盪調整，百普賽斯跌超10%，萬邦醫藥、百花醫藥、千金藥業、博濟醫藥、諾思格跌超5%。

中信證券：創新藥出海漸入佳境，板塊進入盈利拐點

英硅智能(03696)：公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組

滙豐：將諾華製藥的評級上調至「持有」，目標價110瑞士法郎。

艾伯維高管：穩健資產負債表與長期成長空間並存，公司可兼顧早期及晚期業務拓展機會——電話會議實錄

心血管新藥研發遇困局：諾華重磅臨床折戟 Lp（a）指標降了但心血管疾病風險沒降

每日经济新闻

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

賽諾醫療：關於參加上海證券交易所科創板2026年半年度醫療器械及醫療設備行業集體業績説明會的公告

【券商聚焦】中郵證券維持翰森製藥（03692）買入評級指創新藥成增長核心

2026國談第五日：商保創新藥目錄價格協商開始多家藥企攜核藥、CAR-T新藥等重磅藥物進場

2026國談第五日：商保創新藥目錄價格協商開始多家藥企攜核藥、CAR-T新藥等重磅藥物進場

國家醫保局全面完成40批立項指南編制工作全國醫療服務收費邁入統一新階段

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/MEDX/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":35.2363,"timestamp":1789761600000,"preClose":35.4862,"halted":0,"volume":732,"hourTrading":{"tag":"盘后","latestPrice":35.25,"preClose":35.2363,"latestTime":"16:10 EDT","volume":6,"amount":211.4178,"timestamp":1789762204085,"change":0.0137,"changeRate":0.000389,"amplitude":0},"delay":0,"changeRate":-0.007042174140933566,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"休市中","change":-0.2499,"latestTime":"09-18 16:00:00 EDT","open":35.25,"high":35.25,"low":35.2363,"amount":25837,"amplitude":0.000386,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":35.4862,"sharesOutstanding":569946,"nav":35.46,"aum":16664285.16,"dividendRate":0.011607,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.25,"preClose":35.2363,"latestTime":"16:10 EDT","volume":6,"amount":211.4178,"timestamp":1789762204085,"change":0.0137,"changeRate":0.000389,"amplitude":0},"volumeRatio":1.0469104706622006},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0469104706622006,"shares":469946,"dividePrice":0.409,"high":35.25,"amplitude":0.000386,"preClose":35.4862,"low":35.2363,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":35.2363,"eps":0,"divideRate":0.011607,"volume":732,"delay":0,"ttmEps":0,"open":35.25,"prevYearClose":33.2024,"prevWeekClose":34.9572,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":34.9572,"twentyDayClose":37.0138,"sixtyDayClose":34.8443},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666560028","title":"2026年國家醫保目錄談判收官：「三除外」落地，醫保商保雙軌並行，雙目錄如何重構創新藥支付邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560028","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:12","pubTimestamp":1789038763,"startTime":"0","endTime":"0","summary":"9月9日正午，北京西黄城根北街2号全国人大会议中心。最后一家参与商保创新药目录价格协商的企业代表走出大门，历时五天的2026年国家医保目录现场谈判竞价与商保创新药目录价格协商正式收官。新版国家基本医保药品目录与商保创新药目录预计今年11月公布，2027年1月1日起统一执行。五天时间里，124个目录外药品先后完成基本医保谈判竞价，12个创新药冲击商保创新药目录价格协商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870706515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870706515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1574","BK1161","06978","IBBQ","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666622025","title":"諾華製藥(NVS.US)大股東呼籲改組董事會，以改善公司治理。此前該公司股價因連續試驗受挫於本周創下紀錄跌幅。大股東Da","url":"https://stock-news.laohu8.com/highlight/detail?id=2666622025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666622025?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:25","pubTimestamp":1789035953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765489.SGD","IE00BJT1NW94.SGD","LU0211331839.USD","IE0009355771.USD","BK4532","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","BK4007","BK4578","PPH","SYLD","BK4585","IE00B2B36J28.USD","MEDX","IE00B4R5TH58.HKD","WCEO","BK4588","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666562462","title":"Artisan Partners：在藥物試驗接連受挫後 諾華應在董事會層面進行改組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666562462","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666562462?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:23","pubTimestamp":1789035834,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4578","BK4585","NVS","IE00BJT1NW94.SGD","LU0320765489.SGD","IE0009355771.USD","LU0070302665.USD","MEDX","BK4532","PPH","BK4588","LU0211331839.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666648561","title":"信立泰重啓H股IPO，創新藥收入站上半壁江山，仍存單品依賴隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2666648561","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666648561?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 17:29","pubTimestamp":1789032552,"startTime":"0","endTime":"0","summary":"业务层面，信立泰转型取得阶段性成果的同时，核心产品收入集中的风险始终悬而未决。作为转型最重要的产品，信立坦2024 年销售额约 15 亿元，是公司创新药板块最主要的收入来源，公司创新药板块收入高度依赖这一款降压药物。虽然后续信超妥、复立坦、复立安等多款创新产品陆续获批、纳入医保，形成产品梯队，但是这些新产品体量尚小，短期内难以替代信立坦的收入贡献，公司仍然处于单品依赖阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789029785904368871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0196","IPOS","BK0239","LNGR","KCE","IBBQ","06978","BK1161","BK0188","MEDX","REDS","BK0028","BK1574","BK0187","BK4127","BK0183","002294","159992","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666693435","title":"ETF日報(09.10)丨臨床風險事件擾動等多因素疊加，創新藥板塊回落 銀行股温和普漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2666693435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666693435?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:43","pubTimestamp":1789029788,"startTime":"0","endTime":"0","summary":"临床风险事件扰动等多因素叠加，创新药板块集体回落；定增政策红利释放、中报验证盈利韧性，银行板块温和普涨。行业表现临床风险事件扰动、海外利率预期反复与资金风格轮动三重因素叠加，创新药板块集体回落。截至收盘，恒生创新药ETF华泰柏瑞跌2.93%，报1.356元；港股通创新药ETF工银跌2.67%，报1.132元；港股创新药ETF广发跌2.65%，报1.251元。截至收盘，银行AH优选ETF招商涨1.65%，报1.603元；银行ETF汇添富涨1.56%，报1.5元；银行ETF华夏涨1.39%，报1.829元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LNGR","PY","VTV","DFLV","BK4588","BK1161","SPVM","CGVV","ROPE","BKDV","BK1574","FDN","MEDX","VALQ","TALV","IBBQ","SWP","VLUE","EQRR","ABEQ","06978","BK4550","VMAX","159992","VUSV","PRF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666755282","title":"透景生命(300642.SZ)控股子公司申報醫療器械註冊獲得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666755282","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666755282?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:50","pubTimestamp":1789012238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透景生命(300642.SZ)发布公告，公司控股子公司上海脉示生物技术有限公司申报的医疗器械注册申请于近日获得了上海市药品监督管理局的受理，产品名称：四项抗癫痫药物浓度测定试剂盒(液相色谱串联质谱法)。该产品用于检测人体血清样本中的丙戊酸、奥卡西平代谢物(10,11-二氢-10-羟基卡马西平)、托吡酯、左乙拉西坦浓度。临床上用于丙戊酸、奥卡西平代谢物(10,11-二氢-10-羟基卡马西平)、托吡酯、左乙拉西坦血药浓度的监测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","IEIH","BK1583","PTH","BK0042","09996","MDEV","LNGR","BK1574","BK1100","AGNG","GDOC","300642","HART","MEDX","LGHT","BK0046","RSPH","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"東北證券：創新藥BD和商業化持續兑現 CXO超預期，傳統板塊築底拐點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666513175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下：创新药板块：海外创新药产业高景气延续，国产药企有望承接红利Pharma依托多元路径实现营收稳健增长，Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长，这与CXO板块公司的半年度业绩相印证，进一步确认了板块的中期产业趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK1574","159992","BK0028","06978","MEDX","000686","LNGR","CXO","BK0276","BK1161","WX","BK0188","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666746559","title":"創新藥概念股震盪調整，百普賽斯跌超10%，萬邦醫藥、百花醫藥、千金藥業、博濟醫藥、諾思格跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666746559","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666746559?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:49","pubTimestamp":1789004940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555207","title":"中信證券：創新藥出海漸入佳境，板塊進入盈利拐點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555207","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555207?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:24","pubTimestamp":1788999885,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555270","title":"英硅智能(03696)：公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555270?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:20","pubTimestamp":1788999632,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能 发布公告，公司管线中领先的AI驱动候选创新药物 Rentosertib，已于北京协和医院完成III期临床试验的首例患者入组及给药;同日，上海市肺科医院亦完成了其在该试验的首例患者入组。GENESIS-IPF-3为一项评估Rentosertib用于特发性肺纤维化患者的III期临床试验。本试验旨在评估Rentosertib是否能比IIa期研究提供涵盖更大患者群体、且更长时间治疗的临床意义上的获益。Rentosertib透过抑制TNIK，旨在阻断或逆转纤维化进程，为IPF患者提供具备疾病改善潜力的治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AIBU","QQA","QQQ","QMAR","TARK","NBDS","MFIG","GPIQ","AGIX","MEDX","LNGR","NEWZ","MVPS","VUSE","OGIG","CWC","PBOT","159992","GK","AIQU","PSQ","AQGX","CPNQ","161631","PSYK","TQQQ","06978","ARTY","IBBQ","AIFD","QID","QTOC","DQJN","BMED","IBBJ","QQQX","LCLG","NJAN","WPAI","NJUL","KOMP","QSWN","MDTX","03696","NOCT","TQQY","TECY","CHAT","FWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666553725","title":"滙豐：將諾華製藥的評級上調至「持有」，目標價110瑞士法郎。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666553725","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666553725?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 07:44","pubTimestamp":1788997467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4578","IE0009355771.USD","MEDX","BK4532","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","NVS","BK4585","BK4007","BK4588","LU0070302665.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","IE00BJT1NW94.SGD","FXF","IE00BFTCPJ56.SGD","LU0211331839.USD","PPH","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191303955","title":"艾伯維高管：穩健資產負債表與長期成長空間並存，公司可兼顧早期及晚期業務拓展機會——電話會議實錄","url":"https://stock-news.laohu8.com/highlight/detail?id=1191303955","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191303955?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 22:56","pubTimestamp":1788965760,"startTime":"0","endTime":"0","summary":"在近日一场备受关注的电话会议中，艾伯维公司高管明确表示，凭借其稳健的资产负债表以及充裕的长期增长跑道，公司目前能够同时审视并把握早期与晚期阶段的业务拓展契机。这一表态暗示，这家制药巨头在战略布局上拥有充分的灵活性与多元选择空间，既可着眼于处于萌芽阶段的创新资产，亦不排除对相对成熟项目的果断介入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU1670628061.USD","LU2237443978.SGD","LU2357627491.SGD","LU0128525929.USD","IE0002141913.USD","IE0009355771.USD","LU0965509283.SGD","IE000SO60NU8.SGD","LU0943347566.SGD","IE00B4R5TH58.HKD","LU1551013425.SGD","LU2125909247.SGD","LU1496350502.SGD","LU1551013342.USD","LU1934455277.USD","SG9999015978.USD","BK4533","LU0124676726.USD","BK4559","LU0211328371.USD","LU0432979614.USD","IE000F7OJYX1.SGD","LU0861579265.USD","IYH","LU2237443549.SGD","LU1923622614.USD","LU1074936037.SGD","LU1718418525.SGD","LU1003077747.HKD","LU1023059063.AUD","LU0708994859.HKD","LU0203345920.USD","LU1839511570.USD","LU0456855351.SGD","IE00B42XCP33.USD","LU2089283258.USD","LU1670627923.USD","LU2347655073.USD","IE000MB6IJN5.SGD","LU2089984988.USD","LU0942090050.USD","LU0289739699.SGD","LU1989771016.USD","IE000WAW04H5.SGD","LU0029864427.USD","LU0912757837.SGD","LU0203347892.USD","LU0689472784.USD","LU0738911758.USD","LU0795875169.SGD","LU1267930490.SGD","LU2112291526.USD","LU2129689431.USD","LU0289961442.SGD","LU1057294990.SGD","LU2433249047.HKD","IE00BN8TJ469.HKD","LU1093756168.USD","LU0289739343.SGD","LU0310800379.SGD","LU1732800096.USD","LU1934455863.HKD","LU2133065610.SGD","LU1236620834.HKD","SG9999015986.USD","VHT","IE00B19Z3581.USD","LU0985320562.USD","LU2237443382.USD","GLAM","LU1244550494.USD","BK4550","LU0198837287.USD","LU1093756325.SGD","TRUH","LU0158827948.USD","LU0545039389.USD","LU1929549753.HKD","LU1244550577.SGD","LU0256863902.USD","SG9999001440.SGD","LU0965509101.SGD","IE00B3PB1722.GBP","SG9999003800.SGD","FTXH","LU0256863811.USD","LU0882574055.USD","MEDX","IE000BZT7R73.USD","LU2129689605.HKD","LU0472753341.HKD","LU2237443895.HKD","LU2237443622.USD","LU2347655156.SGD","LU1061106388.HKD","RXL","LU0511384066.AUD","IE0002270589.USD","IE00BBT3K403.USD","LU0823416689.USD","LU2125909593.SGD","LU0726765562.USD","JDOC","IE0004445239.USD","LU0820561818.USD","IE00BLSP4452.SGD","XLV","BK4585","LU0320765646.SGD","LU1037948541.HKD","LU2089284900.SGD","LU2129689514.USD","BK4566","PPH","LU0170899867.USD","FHLC","LU0949170772.SGD","LU0661504455.SGD","IE00BVYPNW00.USD","IE00BLSP4239.USD","SG9999011175.SGD","IE0000B7K699.USD","LU1732799900.SGD","BK4588","LU1291159041.SGD","AGNG","LU0417517546.SGD","LU1934455194.USD","LU0122379950.USD","BK4139","LU0868494708.USD","LU0395794307.EUR","LU0965508806.USD","LU0820561909.HKD","LU0098860793.USD","LU0057025933.USD","BK4534","LU0553294199.USD","LU1496350171.SGD","LU1983299246.USD","LU0058720904.USD","LU0689626769.HKD","LU1236620750.USD","IE00BDGV0183.EUR","SG9999015945.SGD","IE00BVYPNV92.GBP","LU1989772923.USD","IXJ","LU1989772840.SGD","LU1037948897.HKD","IE00BJJMRZ35.SGD","LU0859254822.USD","LU1585245621.USD","LU2023251221.USD","LU0069063385.USD","LU2237443465.HKD","IE00BGHQF631.EUR","PJP","LU0114720955.EUR","LU1162221912.USD","SG9999015952.SGD","LU1430594728.SGD","IE00B19Z3B42.SGD","LU0211327993.USD","LU0795875086.SGD","BK4581","LU0234570918.USD","LU0868494617.USD","ABBV","LU1244550221.USD","LU0965509010.AUD","LU0234572021.USD","LU0310799852.SGD","IE00BFTCPJ56.SGD","LU2468319806.SGD","IE00B2B36J28.USD","LU2087621335.USD","LU1267930573.SGD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666531862","title":"心血管新藥研發遇困局：諾華重磅臨床折戟 Lp（a）指標降了但心血管疾病風險沒降","url":"https://stock-news.laohu8.com/highlight/detail?id=2666531862","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666531862?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 22:52","pubTimestamp":1788965533,"startTime":"0","endTime":"0","summary":"9月4日，诺华与Ionis合作开发的Lp（a）〔即：脂蛋白（a）——编者注〕靶向药物pelacarsen的Lp（a）HORIZONⅢ期临床试验公布结果。这款被行业寄予厚望的候选药物，虽能大幅降低Lp（a）水平，却未能显著降低心血管事件风险，给全球心血管创新药赛道投下了一片不确定性阴影。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093869631090.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093869631090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BJJMRZ35.SGD","NVS","MEDX","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0208291251.USD","BK4532","IE00BJT1NW94.SGD","LU0320765489.SGD","BK4585","LU0070302665.USD","LU0211331839.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4588","IE0009355771.USD","PPH","BK4007","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666356195?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2322448791.USD","BK4588","BK1574","HK0000306701.USD","HK0000320264.USD","IBBQ","LU1992135472.HKD","MEDX","BK4585","LU2473716301.USD","LU2272731865.HKD","PPH","06978","LU2272731782.SGD","IBB","XPH","HK0000306685.HKD","BK1161","IE00B5TLWC47.USD","LU2272731600.USD","HK0000320223.HKD","LU2322448957.HKD","02696","159992","HK0000165453.HKD","LU1992135399.USD","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533226","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533226","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533226?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:54","pubTimestamp":1788958467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731782.SGD","IBBQ","LU1992135472.HKD","IBB","LU2322448957.HKD","XPH","LNGR","LU2272731600.USD","LU2272731865.HKD","PPH","BK4585","LU1992135399.USD","LU2322448791.USD","IE00B5TLWC47.USD","BK4588","LU2473716301.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582190","title":"賽諾醫療：關於參加上海證券交易所科創板2026年半年度醫療器械及醫療設備行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582190","media":"同花顺","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582190?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:39","pubTimestamp":1788950340,"startTime":"0","endTime":"0","summary":"    证券日报网讯9月9日，赛诺医疗发布公告称，公司计划于2026年9月17日15：00-17：00参加上海证券交易所组织的科创板2026年半年度医疗器械及医疗设备行业集体业绩说明 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679749361.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679749361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["GDOC","09996","HART","LNGR","159883","MDEV","AGNG","KSTR","BK4585","MEDX","BK1574","PTH","RSPH","IEIH","BK1583","LGHT","BK4588","XHE","688108","BK0251","BK1100","IHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458356","title":"【券商聚焦】中郵證券維持翰森製藥（03692）買入評級 指創新藥成增長核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458356","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:32","pubTimestamp":1788939161,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指，翰森制药 发布2026年中报，2026H1实现收入83.04亿元，同比增长11.7%；归母净利润42.58亿元，同比增长35.8%，利润高增部分得益于约6.31亿元的投资收益等一次性项目。创新药已成为公司增长的绝对核心。创新药收入达70.92亿元，同比增长15.4%，占总收入比重由去年同期的82.7%提升至85.4%。其中抗肿瘤领域收入54.73亿元，占总收入65.9%；非肿瘤领域收入28.31亿元，占总收入34.1%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991138","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","159992","LNGR","161027","03692","06978","MEDX","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666305240","title":"2026國談第五日：商保創新藥目錄價格協商開始 多家藥企攜核藥、CAR-T新藥等重磅藥物進場","url":"https://stock-news.laohu8.com/highlight/detail?id=2666305240","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666305240?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 09:06","pubTimestamp":1788915970,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","IBBQ","LNGR","BK1574","MEDX","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666303231","title":"2026國談第五日：商保創新藥目錄價格協商開始 多家藥企攜核藥、CAR-T新藥等重磅藥物進場","url":"https://stock-news.laohu8.com/highlight/detail?id=2666303231","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666303231?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 08:20","pubTimestamp":1788913212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666303973","title":"國家醫保局全面完成40批立項指南編制工作 全國醫療服務收費邁入統一新階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666303973","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666303973?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 08:12","pubTimestamp":1788912732,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":10,"totalSize":260,"code":"91000000","status":"200"}]}}